Use of agents that modulate PDE11A activity
AssigneePfizer Inc.
InventorsMartyn Frank Burslem, Ian Dennis Harrow, Jeremy Lanfear, Stephen Charles Phillips, Christopher Peter Wayman
Life of this patent
Estimating the term…
Abstract
The present invention relates to the effect of PDE11A modulation on male pro-fertility, male contraception, and female sexual dysfunction (FSD), specifically female sexual arousal disorder (FSAD), female orgasmic disorder (FOD), hypoactive sexual desire disorder (HSDD) or sexual pain disorders.
Claims23
A method of modulating in vivo or ex vivo spermatozoa capacitation, said method comprising administering an agent that modulates PDE11A activity.
Use of an agent that modulates PDE11A activity in the manufacture of a medicament for modulating in vivo or ex vivo spermatozoa capacitation.
Use of an agent that increases PDE11A activity in the manufacture of a medicament for decreasing in vivo or ex vivo spermatozoa capacitation.
Use of an agent that reduces PDE11A activity as a male pro-fertility agent, wherein said male pro-fertility agent is used ex vivo.
Use of an agent that increases PDE11A activity as a male pro-fertility agent, wherein said male pro-fertility agent is used in vivo.
Use of an agent that increases spermatozoa capacitation as a male pro-fertility agent, wherein said male pro-fertility agent is used ex vivo.
Use of an agent that reduces spermatozoa capacitation as a male pro-fertility agent, wherein said male pro-fertility agent is used in vivo.
Use of an agent that reduces PDE11A activity as a male contraceptive agent, wherein said male contraceptive agent is used in vivo.
Use of an agent that increases PDE11A activity as a male contraceptive agent, wherein said male contraceptive agent is used ex vivo.
Use of an agent that increases spermatozoa capacitation as a male contraceptive agent, wherein said male contraceptive agent is used in vivo.
Use of an agent that reduces spermatozoa capacitation as a male contraceptive agent, wherein said male contraceptive agent is used ex vivo.
A method of preventing or treating female sexual dysfunction (FSD), said method comprising administering to a female mammal an agent that stimulates, activates, enhances or agonises PDE11A activity.
Use of an agent that stimulates, activates, enhances or agonises PDE11A activity in the manufacture of a medicament for the prevention or treatment of female sexual dysfunction (FSD).
A method of preventing or treating female sexual dysfunction (FSD), said method comprising administering to a female mammal an agent that inhibits, decreases, deactivates or antagonises PDE11A activity.
Use of an agent that inhibits, decreases, deactivates or antagonises PDE11A activity in the manufacture of a medicament for the prevention or treatment of female sexual dysfunction (FSD).
Dependencies are inferred from the claim text.